To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.6635465.
Breakthrough pain (BTP) has great repercussions on the quality of life, and on the use of health resources. The scope of BTP costs in cancer patients is unknown. The purpose of this study was to evaluate the economic cost of BTP in patients with cancer and the relationship with their quality of life.
A 1-month observational prospective cost-of-illness study was designed. The patients recorded the consumption of health resources and drugs related to BTP in a diary. The current symptoms in Edmonton Symptoms Assessment Scale (ESAS) and their quality of life (EORTC QLQ-C30, version 3) were assessed. The direct medical and non-medical costs fixed and variable and the indirect costs of the patient and the caregivers were evaluated. Factors related to cost and quality of life were identified using linear generalized models (LGM) type gamma and logistic link. Participants were oncologic patients with BTP, older than 18 years, with controlled basal pain.
Eight Spanish pain units, eight palliative care units, and one oncology department included 152 patients. One hundred patients (65.8%) were male and the mean age was 66.8 years (95% CI 64.8–68.8). The total cost per patient was 2941.60 euros per month: 88% direct medical costs, 5% non-medical direct costs, and 7% indirect costs due to lost productivity. A better score in EORTC QLQ-30 quality of life was associated with a reduction in overall costs.
The study showed the results of the first real-life prospective study evaluating the cost of illness of BTP in cancer patients demonstrating that the presence of breakthrough pain in a cancer patient causes a very significant increase in healthcare costs.
Kyowa Kirin Farmacéutica, S.L.U.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331–8.
Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Sympt Manage. 2002;24(1):45–52. CrossRef
Porta-sales J, Garzón C, Juliá J, Casals Merchán M. Dolor irruptivo en cáncer. Med Clin. 2010;135(6):280–5. CrossRef
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273–81. CrossRef
Escobar Álvarez Y, Biete i Solà A, Camba Rodríguez M et al. Diagnóstico y tratamiento del dolor irruptivo oncológico: Recomendaciones de consenso. Med Paliat. 2013;20(4):150–7. CrossRef
Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47(1):57–76. CrossRef
Nekolaichuck CL, Fainsinger RL, Lawlor PG. A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med. 2005;19(6):466–76. CrossRef
Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25(1):9–18. CrossRef
Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44. CrossRef
Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care. 2008;14:S129–40. PubMed
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187–93. CrossRef
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9. PubMed
Badia X, Muriel C, Gracia A, et al. Validation of the Spanish version of the brief Pain Inventory in patients with oncological pain. Med Clin (Barc). 2003;120(2):52–9. CrossRef
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. CrossRef
Fayers PM, Aaronson NK, Bjordal K, et al., on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual, 3rd edition. European Organisation for Research and Treatment of Cancer, Brussels 2001.
Spanish Cost Database, e-salud. Oblikue consulting: http://www.oblikue.com/bddcostes/. Accessed 10 Nov 2017.
BotPlus 2.0. Consejo General de Colegios Oficiales de Farmacéuticos. https://botplusweb.portalfarma.com/. Accessed 10 Nov 2017.
Informe del IMSERSO. Las personas mayores en España. Informe 2008. http://www.imserso.es/InterPresent2/groups/imserso/documents/ binario/infppmm2008vol1.pdf. Accessed 10 Nov 2017.
Van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004;5(1):36–45. CrossRef
Encuesta trimestral del coste laboral. Instituto Nacional de Estadística. http://www.ine.es/daco/daco42/etcl/etcl0316.pdf. Accessed 10 Nov 2017.
Glick HA, Doshi JA, Sonnad SS, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2014. CrossRef
Arrospide A, Soto-Gordoa M, Acaiturri T, López-Vivanco G, Abecia LC, Mar J. Coste del tratamiento del cáncer de mama por estadio clínico en el País Vasco. Rev Esp Salud Pública. 2015;89(1):93–7. CrossRef
Scott NW, Fayers PM, Aarouson NK et al. EORTC QLQ-C30 Reference Values, 2008. http://groups.eortc.be/qol/manuals. Accessed 29 June 2018.
Fortner BV, Okon TA, Ashley J, et al. The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage. 2003;25(4):334–43. CrossRef
Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27(2):167–75. CrossRef
Velucci R, Mediati RD, Gasperoni S, et al. Pharmacoeconomic considerations about breakthrough cancer pain. Value Health. 2015;18(7):A665–6. https://doi.org/10.1016/j.jval.2015.09.2426. CrossRef
Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med. 2007;8(3):281–8. CrossRef
- Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study
Antonio Javier Jiménez-López
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II